HC Wainwright Reiterates Buy Rating for Cerecor Inc (CERC)

Cerecor Inc (NASDAQ:CERC)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Sunday. They currently have a $15.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 205.81% from the company’s previous close.

Shares of Cerecor (NASDAQ:CERC) opened at 4.905 on Friday. The company’s market capitalization is $42.43 million. Cerecor has a 52-week low of $1.94 and a 52-week high of $6.65. The firm’s 50-day moving average price is $4.13 and its 200 day moving average price is $3.41.

Cerecor (NASDAQ:CERC) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.15. On average, equities analysts forecast that Cerecor will post ($1.97) earnings per share for the current year.

About Cerecor

Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.

5 Day Chart for NASDAQ:CERC

Receive News & Ratings for Cerecor Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.